Comprehensive Analysis of Expression and Pathway for CD27 in Esophageal Cancer

Overview

Journal Mol Biotechnol

Publisher Springer

Specialties Biotechnology
Molecular Biology

Date 2023 Aug 16

PMID 37584826

Authors

Fan-Kai Xiao

Lin Wang

Affiliations

Soon will be listed here.

Abstract

CD27 as a marker of memory B cells is belong to the tumor necrosis factor receptor (TNFR) superfamily, CD27 is ligated by CD70, they can co-stimulate T-cell growth and differentiation through their interaction. Uncertainty surrounds CD27's function in esophageal cancer (EC). This study investigated the role of CD27 in the prognosis of EC using the TCGA, cbioportal, linkedomics and GEPIA databases as well as the proliferation assay was applied. CD27 differential expression may be a key factor in the development of EC. different level of CD27 expression in EC has profound impacts on TOR complex, and many kinds of kinase (KIT proto-oncogene receptor tyrosine kinase, transforming growth factor beta receptor 1, and G protein-coupled receptor kinase 3.), as well as the cell membrane, and survival analysis revealed that it had a significant impact on both the overall survival and disease-free survival of EC. CD27 overexpression will suppress the viability of the KYSE150 and TE3 cells. Our findings suggested that the degree of CD27 expression could serve as an esophageal cancer prognosis biomarker.

References

Uhlenhopp D, Then E, Sunkara T, Gaduputi V . Epidemiology of esophageal cancer: update in global trends, etiology and risk factors. Clin J Gastroenterol. 2020; 13(6):1010-1021. DOI: 10.1007/s12328-020-01237-x. View

Watanabe M, Otake R, Kozuki R, Toihata T, Takahashi K, Okamura A . Recent progress in multidisciplinary treatment for patients with esophageal cancer. Surg Today. 2019; 50(1):12-20. PMC: 6952324. DOI: 10.1007/s00595-019-01878-7. View

Short M, Burgers K, Fry V . Esophageal Cancer. Am Fam Physician. 2017; 95(1):22-28. View

Sanmamed M, Pastor F, Rodriguez A, Perez-Gracia J, Rodriguez-Ruiz M, Jure-Kunkel M . Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS. Semin Oncol. 2015; 42(4):640-55. DOI: 10.1053/j.seminoncol.2015.05.014. View

Wajant H . Therapeutic targeting of CD70 and CD27. Expert Opin Ther Targets. 2016; 20(8):959-73. DOI: 10.1517/14728222.2016.1158812. View

Stetler-Stevenson M, Paiva B, Stoolman L, Lin P, Jorgensen J, Orfao A . Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition. Cytometry B Clin Cytom. 2015; 90(1):26-30. PMC: 7511978. DOI: 10.1002/cyto.b.21249. View

Riether C, Pabst T, Hopner S, Bacher U, Hinterbrandner M, Banz Y . Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. Nat Med. 2020; 26(9):1459-1467. DOI: 10.1038/s41591-020-0910-8. View

Reddy V, Klein C, Isenberg D, Glennie M, Cambridge G, Cragg M . Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples. Rheumatology (Oxford). 2017; 56(7):1227-1237. PMC: 5808665. DOI: 10.1093/rheumatology/kex067. View

Yang Z, Novak A, Ziesmer S, Witzig T, Ansell S . CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells. Blood. 2007; 110(7):2537-44. PMC: 1988926. DOI: 10.1182/blood-2007-03-082578. View

10.

Schizas D, Charalampakis N, Kole C, Mylonas K, Katsaros I, Zhao M . Immunotherapy for esophageal cancer: a 2019 update. Immunotherapy. 2020; 12(3):203-218. DOI: 10.2217/imt-2019-0153. View

11.

Buchan S, Rogel A, Al-Shamkhani A . The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy. Blood. 2017; 131(1):39-48. DOI: 10.1182/blood-2017-07-741025. View

12.

Starzer A, Berghoff A . New emerging targets in cancer immunotherapy: CD27 (TNFRSF7). ESMO Open. 2020; 4(Suppl 3):e000629. PMC: 7082637. DOI: 10.1136/esmoopen-2019-000629. View

13.

Beauchamp E, Platanias L . The evolution of the TOR pathway and its role in cancer. Oncogene. 2012; 32(34):3923-32. DOI: 10.1038/onc.2012.567. View

14.

Kaminska K, Szczylik C, Bielecka Z, Bartnik E, Porta C, Lian F . The role of the cell-cell interactions in cancer progression. J Cell Mol Med. 2015; 19(2):283-96. PMC: 4407603. DOI: 10.1111/jcmm.12408. View

15.

Kose D, Guzelcicek A, Oz O, Erdem A, Haliloglu Y, Witzel M . The Mutation of CD27 Deficiency Presented With Familial Hodgkin Lymphoma and a Review of the Literature. J Pediatr Hematol Oncol. 2022; 44(4):e833-e843. DOI: 10.1097/MPH.0000000000002453. View

16.

Remedios K, Meyer L, Zirak B, Pauli M, Truong H, Boda D . CD27 Promotes CD4 Effector T Cell Survival in Response to Tissue Self-Antigen. J Immunol. 2019; 203(3):639-646. PMC: 6650327. DOI: 10.4049/jimmunol.1900288. View

17.

Gantner P, Pagliuzza A, Pardons M, Ramgopal M, Routy J, Fromentin R . Single-cell TCR sequencing reveals phenotypically diverse clonally expanded cells harboring inducible HIV proviruses during ART. Nat Commun. 2020; 11(1):4089. PMC: 7427996. DOI: 10.1038/s41467-020-17898-8. View

18.

Flieswasser T, Van den Eynde A, Van Audenaerde J, De Waele J, Lardon F, Riether C . The CD70-CD27 axis in oncology: the new kids on the block. J Exp Clin Cancer Res. 2022; 41(1):12. PMC: 8734249. DOI: 10.1186/s13046-021-02215-y. View

19.

He L, Prostak N, Thomas L, Vitale L, Weidlick J, Crocker A . Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice. J Immunol. 2013; 191(8):4174-83. DOI: 10.4049/jimmunol.1300409. View

20.

Buchan S, Fallatah M, Thirdborough S, Taraban V, Rogel A, Thomas L . PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8 T-Cell-Driven Antitumor Immunity. Clin Cancer Res. 2018; 24(10):2383-2394. PMC: 5959006. DOI: 10.1158/1078-0432.CCR-17-3057. View